Sunita Nathan to Graft vs Host Disease
This is a "connection" page, showing publications Sunita Nathan has written about Graft vs Host Disease.
Connection Strength
4.459
-
Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
Score: 0.694
-
Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplant. 2020 04; 55(4):833-835.
Score: 0.660
-
Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
Score: 0.222
-
Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
Score: 0.220
-
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 01; 108(7):1900-1908.
Score: 0.217
-
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023 04; 98(4):608-619.
Score: 0.210
-
Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
Score: 0.204
-
Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 07; 57(7):1150-1163.
Score: 0.200
-
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
Score: 0.198
-
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther. 2022 06; 28(6):335.e1-335.e17.
Score: 0.193
-
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021 11; 27(11):921.e1-921.e10.
Score: 0.190
-
Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020 05 26; 4(10):2317-2324.
Score: 0.175
-
Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
Score: 0.174
-
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020 03 24; 4(6):983-992.
Score: 0.173
-
Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. Infect Dis Clin North Am. 2019 06; 33(2):331-359.
Score: 0.161
-
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):662-673.
Score: 0.158
-
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):e46-e54.
Score: 0.158
-
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 06 10; 137(23):3291-3305.
Score: 0.047
-
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 08; 190(4):573-582.
Score: 0.043
-
Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
Score: 0.042
-
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
Score: 0.041
-
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
Score: 0.040
-
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
Score: 0.039